Tessa Palmert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tessa Palmert has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Elham Hashemi
Hospital for Sick Children Toronto Ontario Canada
1 shared publicationElias Jabbour
Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre , Montreal, Quebec
1 shared publication- Jonathon R. Campbell
Department of Medicine, McGill University, Montreal, Quebec, Canada
1 shared publication Katie Oranges
Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
1 shared publication- Kyobin Hwang
Hospital for Sick Children Toronto Ontario Canada
1 shared publication Lauren Guidry
Children's Hospital Los Angeles Los Angeles California USA
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6)
Sensitivity of Tuberculosis Infection Diagnostic Tests Among Different Populations: A Systematic Review and Meta-analysis
Background: We aimed to estimate the sensitivity of skin and blood–based tuberculosis (TB) infection tests and assess variation in sensitivity by test type and population characteristics. Methods: We conducted a meta-analysis of studies involving individuals with microbiologically confirmed TB disease (surrogate reference standard) who underwent TB infection testing. Searches were performed across databases up to February 24, 2025. Data were extracted using a standardized form and pooled using random-effects meta-analysis. Primary analyses focused on tests performed before or during TB disease treatment. Results: From 103 031 records, 307 studies were included: 110 evaluated tuberculin skin testing (TST), 185 QuantiFERON (QFT), 107 T-SPOT.TB, 10 antigen-based skin tests, and 5 TB-IGRA. Sensitivity was consistently lower among people with HIV. Among populations without vs with HIV, respectively, TST ≥5 mm sensitivity was 80.3% (95% CI, 73.7%–85.5%) and 53.6% (95% CI, 41.5%–65.4%), TST ≥10 mm sensitivity was 75.1% (95% CI, 68.8%–80.5%) and 64.5% (95% CI, 36.8%–85.0%), antigen-based skin test sensitivity was 77.7% (95% CI, 69.7%–84%) and 61.3% (95% CI, 39.6%–79.3%), QFT sensitivity was 82.6% (95% CI, 80.7%–84.3%) and 66.5% (95% CI, 59.8%–72.6%), and T-SPOT.TB sensitivity was 88.2% (95% CI, 86.2%–90.0%) and 69% (95% CI, 56.6%–79.2%). TB-IGRA was only evaluated in populations without HIV (sensitivity, 85.4%; 95% CI, 81.3%–88.7%). Sensitivity in other populations targeted for TB infection testing generally fell between estimates among people with and without HIV. In comparative analyses, TST ≥5 mm and TST ≥10 mm had comparable sensitivity to QFT; however, T-SPOT.TB had superior sensitivity to both TST ≥5 mm and QFT. Conclusions: TB infection test sensitivity varies by test type and population. All tests showed reduced sensitivity in people with HIV. T-SPOT.TB demonstrated the highest sensitivity across populations.
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6)
Open AccessSensitivity of Tuberculosis Infection Diagnostic Tests Among Different Populations: A Systematic Review and Meta-analysis
Background: We aimed to estimate the sensitivity of skin and blood–based tuberculosis (TB) infection tests and assess variation in sensitivity by test type and population characteristics. Methods: We conducted a meta-analysis of studies involving individuals with microbiologically confirmed TB disease (surrogate reference standard) who underwent TB infection testing. Searches were performed across databases up to February 24, 2025. Data were extracted using a standardized form and pooled using random-effects meta-analysis. Primary analyses focused on tests performed before or during TB disease treatment. Results: From 103 031 records, 307 studies were included: 110 evaluated tuberculin skin testing (TST), 185 QuantiFERON (QFT), 107 T-SPOT.TB, 10 antigen-based skin tests, and 5 TB-IGRA. Sensitivity was consistently lower among people with HIV. Among populations without vs with HIV, respectively, TST ≥5 mm sensitivity was 80.3% (95% CI, 73.7%–85.5%) and 53.6% (95% CI, 41.5%–65.4%), TST ≥10 mm sensitivity was 75.1% (95% CI, 68.8%–80.5%) and 64.5% (95% CI, 36.8%–85.0%), antigen-based skin test sensitivity was 77.7% (95% CI, 69.7%–84%) and 61.3% (95% CI, 39.6%–79.3%), QFT sensitivity was 82.6% (95% CI, 80.7%–84.3%) and 66.5% (95% CI, 59.8%–72.6%), and T-SPOT.TB sensitivity was 88.2% (95% CI, 86.2%–90.0%) and 69% (95% CI, 56.6%–79.2%). TB-IGRA was only evaluated in populations without HIV (sensitivity, 85.4%; 95% CI, 81.3%–88.7%). Sensitivity in other populations targeted for TB infection testing generally fell between estimates among people with and without HIV. In comparative analyses, TST ≥5 mm and TST ≥10 mm had comparable sensitivity to QFT; however, T-SPOT.TB had superior sensitivity to both TST ≥5 mm and QFT. Conclusions: TB infection test sensitivity varies by test type and population. All tests showed reduced sensitivity in people with HIV. T-SPOT.TB demonstrated the highest sensitivity across populations.
- Open Access
- 21 July 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (10) , e31913
Caregiving for Children With Acute Lymphoblastic Leukemia Receiving Home‐Based Blinatumomab: Caregiver Experiences and Recommendations
Background: It is expected that blinatumomab will be increasingly incorporated into the care of children with B‐lineage acute lymphoblastic leukemia (B‐ALL) based on improved survival for subsets of patients and a favorable safety profile. Most of the 28‐day continuous infusion can be administered in outpatient or home settings. Limited studies have described low rates of complications at home when appropriate safety plans are in place. However, home administration shifts the burden of monitoring and care to caregivers.Procedure: Caregivers of children with B‐ALL within 1 month of completing a first cycle of blinatumomab at home were recruited from three tertiary care centers and participated in virtual, audio‐recorded, semi‐structured interviews, with translation services available as required. Interviews were transcribed, coded independently in duplicate, and analyzed using thematic analysis. Identified caregiving context‐specific barriers and facilitators were coded deductively.Results: Participating caregivers (n = 21) described a time‐bound confidence response where initial infusion anxiety was gradually replaced with caregiving self‐assurance. Growing confidence co‐occurred with improved caregiver wellness and child quality of life, characterized by resuming more usual family activities amid therapy. Barriers and facilitators to successful home‐based blinatumomab included caregiver knowledge and skills, access to hospital‐based support, and particular aspects of a family's social and material environment, and these underpinned recommendations for future caregivers.Conclusions: Caregivers can confidently manage home‐based continuous infusion blinatumomab with anticipatory guidance and support, and with attention paid to context‐related modifiers to care. Caregiver insights should be reflected in the principles that become the basis of future pediatric B‐cell ALL clinical trials and care.
- 21 July 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (10) , e31913
Open AccessCaregiving for Children With Acute Lymphoblastic Leukemia Receiving Home‐Based Blinatumomab: Caregiver Experiences and Recommendations
Background: It is expected that blinatumomab will be increasingly incorporated into the care of children with B‐lineage acute lymphoblastic leukemia (B‐ALL) based on improved survival for subsets of patients and a favorable safety profile. Most of the 28‐day continuous infusion can be administered in outpatient or home settings. Limited studies have described low rates of complications at home when appropriate safety plans are in place. However, home administration shifts the burden of monitoring and care to caregivers.Procedure: Caregivers of children with B‐ALL within 1 month of completing a first cycle of blinatumomab at home were recruited from three tertiary care centers and participated in virtual, audio‐recorded, semi‐structured interviews, with translation services available as required. Interviews were transcribed, coded independently in duplicate, and analyzed using thematic analysis. Identified caregiving context‐specific barriers and facilitators were coded deductively.Results: Participating caregivers (n = 21) described a time‐bound confidence response where initial infusion anxiety was gradually replaced with caregiving self‐assurance. Growing confidence co‐occurred with improved caregiver wellness and child quality of life, characterized by resuming more usual family activities amid therapy. Barriers and facilitators to successful home‐based blinatumomab included caregiver knowledge and skills, access to hospital‐based support, and particular aspects of a family's social and material environment, and these underpinned recommendations for future caregivers.Conclusions: Caregivers can confidently manage home‐based continuous infusion blinatumomab with anticipatory guidance and support, and with attention paid to context‐related modifiers to care. Caregiver insights should be reflected in the principles that become the basis of future pediatric B‐cell ALL clinical trials and care.